InterMune, Inc.

InterMune is a biopharmaceutical company focused on developing therapies in pulmonary and hepatology.

Business

Revenue:

Currency Amount Valid Date
  • 48,150,000
  • Dec 31, 2008
  • 90,800,000
  • Dec 31, 2006
View entire collection »

Operating Income:

Currency Amount Valid Date
  • -73,710,000
  • Dec 31, 2006

Net profit:

Currency Amount Valid Date
  • -97,740,000
  • Dec 31, 2008

Cash:

Currency Amount Valid Date
  • 63,770,000
  • Dec 31, 2008

Current Assets:

Currency Amount Valid Date
  • 144,990,000
  • Dec 31, 2008

Total Assets:

Currency Amount Valid Date
  • 172,220,000
  • Dec 31, 2008

Current Liabilities:

Currency Amount Valid Date
  • 48,310,000
  • Dec 31, 2008

Total Liabilities:

Currency Amount Valid Date
  • 297,100,000
  • Dec 31, 2008

Retained Earnings:

Currency Amount Valid Date
  • -755,430,000
  • Dec 31, 2008
top ↑ top ↑ top ↑

Similar topics in Freebase

  • QLT Inc.

  • Ozelle Pharmaceuticals Inc.

  • Dendreon

    Dendreon (NASDAQ: DNDN) is a Seattle based biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer. It consists of a mixture of the patient's own blood cells (autologous, with dendritic cells thought to be the most important)...
  • Corcept Therapeutics Incorporated

  • Alexion Pharmaceuticals

  • Johnson & Johnson

    Johnson & Johnson (NYSE: JNJ) is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturer founded in 1886. Its common stock is a component of the Dow Jones Industrial Average and the company is listed among the Fortune 500. Johnson & Johnson consistently...

These people have edited this topic:

Edit this topic
Edit and Show details

Add or delete facts, download data in JSON or RDF formats, and explore topic metadata.

Freebase Logo
What is Freebase?

Freebase is a huge collection of facts, built by people like you. Freebase connects facts in ways other sites can't, giving you new ways to explore millions of subjects.
You can help improve it!